BMS Reports EXCALIBER-RRMM Results for ZENBEXUS
PRINCETON, N.J. — September 26, 2026 Bristol Myers Squibb announced the first presentation of results from the pivotal Phase...
Multiple Myeloma
Advertisement
Adaptive Highlights MRD Testing in New Myeloma Cure Definition
SEATTLE — September 25, 2026 Adaptive Biotechnologies highlighted a new consensus definition of cure for multiple myeloma presented at...
C4 Therapeutics Presents Cemsidomide Biomarker Data in Multiple Myeloma
WATERTOWN, Mass. — September 25, 2026 C4 Therapeutics presented new biomarker data from clinical trials of cemsidomide in patients...
Adaptive Highlights Updated NCCN MRD Guidance in Multiple Myeloma
SEATTLE, Wash. — September 17, 2026 Adaptive Biotechnologies highlighted updates to the National Comprehensive Cancer Network (NCCN) Guidelines for...
Johnson & Johnson TECVAYLI Gains Positive CHMP Opinion
Raritan, New Jersey, U.S., September 18, 2026 Johnson & Johnson has announced that the European Medicines Agency’s Committee for...
Advertisements
BMS Reports Positive Phase 2 CAR T Cell Trial Results
Princeton, New Jersey, U.S., September 8, 2026 Bristol Myers Squibb (BMS) has announced positive topline results from the registrational...
AbbVie Reports Positive Phase 3 Etentamig Results
North Chicago, Illinois, USA, September 3, 2026 AbbVie has announced positive topline results from the Phase 3 CERVINO trial,...
C4 Therapeutics to Present Cemsidomide Biomarker Data in Multiple Myeloma
Watertown, Mass., September 3, 2026 C4 Therapeutics announced that new biomarker data evaluating the immunomodulatory effects of cemsidomide in...
HaemaLogiX Advances KMCAR™ T-Cell Clinical Program
SYDNEY, Australia, August 26, 2026 HaemaLogiX Ltd has announced a key clinical development milestone with the first patient successfully...
Johnson & Johnson Expands TECVAYLI for Multiple Myeloma Care
Beerse, Belgium, August 21, 2026 Johnson & Johnson announced that the European Commission (EC) has approved an indication extension...
Advertisement
